EIKN vs ENGN

Eikon Therapeutics, Inc. vs enGene Therapeutics Inc. — Valuation Comparison 2026

EIKN

Biological Products, (No Diagnostic Substances)
Eikon Therapeutics, Inc.
Quality
1.7
out of 10
Value Trap
Price
$10.84
Last close
Models
7/13
Active
VS

ENGN

Biological Products, (No Diagnostic Substances)
enGene Therapeutics Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.85
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType EIKN Fair ValueEIKN Upside ENGN Fair ValueENGN Upside
Bayesian DCF Intrinsic $2.80 -74.1% $0.54 -70.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $15.52 +43.2% $1.93 +4.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $5.58 -48.5% $2.00 +8.0%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EIKN vs ENGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EIKN vs ENGN — Which Stock Is More Undervalued?

ENGN scores higher with a 4.1/10 quality rating vs EIKN's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Eikon Therapeutics, Inc. (EIKN) and enGene Therapeutics Inc. (ENGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EIKN currently trades at $10.84 with a QOC of 1.7/10, while ENGN trades at $1.85 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).